Shopping Cart
Remove All
Your shopping cart is currently empty
GV-58 is a selective N- and P/Q-type Ca2+ channels agonist (EC50: 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel). The inhibitory of GV-58 is 20-fold fewer for CDK kinases activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $47 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $228 | In Stock | In Stock | |
| 25 mg | $455 | In Stock | In Stock | |
| 50 mg | $657 | In Stock | In Stock | |
| 100 mg | $918 | In Stock | In Stock | |
| 500 mg | $1,830 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $162 | In Stock | In Stock |
| Description | GV-58 is a selective N- and P/Q-type Ca2+ channels agonist (EC50: 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel). The inhibitory of GV-58 is 20-fold fewer for CDK kinases activity. |
| Targets&IC50 | Ca2+ channel, N-type:7.21 uM, Ca2+ channel, P/Q-type:8.81 uM |
| In vitro | In comparison with the parent molecule, (R)-roscovitine, GV-58 has a 20-fold less potent cyclin-dependent kinase antagonist effect, a 3- to 4-fold more potent Ca2+ channel agonist effect, and 4-fold higher efficacy as a Ca2+ channel agonist. GV-58 had no agonist activity (up to 100 μm) on the L-type α-subunit we tested (Cav1.3). |
| Molecular Weight | 374.5 |
| Formula | C18H26N6OS |
| Cas No. | 1402821-41-3 |
| Smiles | CCCn1cnc2c(NCc3ccc(C)s3)nc(N[C@H](CC)CO)nc12 |
| Relative Density. | 1.33 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (240.32 mM), Sonication is recommended. Methanol: 55 mg/mL (146.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Methanol/DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.